Alkermes Management to Discuss Strategy at TD Cowen Health Care Conference
Event summary
- Alkermes management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026.
- The live webcast will be available on Alkermes' website and archived for 14 days.
- Alkermes focuses on developing innovative medicines in neuroscience, with a portfolio targeting alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy.
- The company's pipeline includes late-stage clinical candidates for narcolepsy and idiopathic hypersomnia, and early-stage development of orexin 2 receptor agonists for ADHD, multiple sclerosis, and Parkinson’s disease.
The big picture
Alkermes' participation in the TD Cowen Health Care Conference underscores its focus on strategic positioning within the neuroscience sector. The company's diverse pipeline and proprietary commercial products place it in a competitive landscape where innovation and regulatory approvals are critical. Investors will be watching for updates on pipeline progress and market dynamics that could influence Alkermes' growth and valuation.
What we're watching
- Pipeline Progress
- How the advancement of late-stage clinical candidates for narcolepsy and idiopathic hypersomnia will impact Alkermes' market position.
- Strategic Shifts
- Whether Alkermes can sustain its growth trajectory in the competitive neuroscience market.
- Market Dynamics
- The pace at which early-stage orexin 2 receptor agonists move through development and potential regulatory approvals.
Related topics